Código QR (código de barras bidimensional)

Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome

Abstract Introduction The safety and efficacy of microbiota-based products in patients with irritable bowel syndrome (IBS) and recurrent Clostridioides difficile infection (rCDI) has not been studied. Fecal microbiota, live-jslm (RBL; REBYOTA®) is an FDA-approved, single-dose, microbiota-based produ...

ver descrição completa

Na minha lista:
Principais autores: Olga C. Aroniadis, Beth Guthmueller, Kaitlin Dehlin, Shivam Srivastava, Paul Feuerstadt, Anthony Lembo, Horst C. Weber
Formato: Artigo
Idioma:Inglês
Publicado em: Adis, Springer Healthcare 2025-08-01
coleção:Infectious Diseases and Therapy
Assuntos:
CDI
Clostridioides difficile
Microbiota-based product
RBX2660
Irritable bowel syndrome
Acesso em linha:https://doi.org/10.1007/s40121-025-01208-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados